United States - English - NLM (National Library of Medicine)

a-s medication solutions - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg - propafenone hydrochloride tablets are indicated to: usage considerations: propafenone hydrochloride tablets are contraindicated in the following circumstances: pregnancy category c. there are no adequate and well-controlled studies in pregnant women. propafenone hydrochloride tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. animal data: teratogenic effects: propafenone has been shown to be embryotoxic (decreased survival) in rabbits and rats when given in oral maternally toxic doses of 150 mg/kg day (about 3 times the maximum recommended human dose [mrhd] on a mg/m2 basis) and 600 mg/kg/day (about 6 times the mrhd on a mg/m2 basis), respectively. although maternally tolerated doses (up to 270 mg/kg/day, about 3 times the mrhd on a mg/m2 basis) produced no evidence of embryotoxicity in rats, post-implantation loss was elevated in all rabbit treatment groups (doses as low as 15 mg/kg/day, about 1/3 the mrhd on a mg/m2 basis). non-teratogenic

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

loveland products inc - non-ionic surfactant blend - liquid - non-ionic surfactant blend emulsifiers & surfactants active 900.0 g/l - wetting agent - wetting agent | spreader | surfactant - tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank

United States - English - NLM (National Library of Medicine)

ethex - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - tablet, film coated - 150 mg - in patients without structural heart disease, propafenone hcl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms. as with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional av refractory period is recommended. the use of propafenone in patients with chronic atrial fibrillation has not been evaluated. propafenone should not be used to control ventricular rate during atrial fibrillation. propafenone is also indicated for the treatment of initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients w

Philippines - English - FDA (Food And Drug Administration)

happy pet products incorporated; distributor: happy pet products incorporated - none - none - none

Philippines - English - FDA (Food And Drug Administration)

happy pet products incorporated.; distributor: happy pet products incorporated. - none - none - none

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - propafenone hydrochloride - film-coated tablet - 300 milligram(s) - antiarrhythmics, class ic; propafenone

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - propafenone hydrochloride - film-coated tablet - 150 milligram(s) - antiarrhythmics, class ic; propafenone

Canada - English - Health Canada

sanis health inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics

Canada - English - Health Canada

sanis health inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg